FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2747484920> ?p ?o ?g. }

• W2747484920 endingPage "1658" @default.
• W2747484920 startingPage "1646" @default.
• W2747484920 abstract "This study compared adenosine-associated pleiotropic effects of the 2 P2Y12 receptor antagonists on vascular function, systemic inflammation, and circulating endothelial progenitor cells (EPCs).Both ticagrelor and prasugrel have potent antiplatelet effects. However, only ticagrelor inhibits cellular uptake of adenosine.Using a randomized, crossover design with 10-week follow-up ticagrelor or prasugrel was administered to type 2 diabetic patients with non-ST-segment elevation acute coronary syndrome requiring stent implantation. A total of 62 patients underwent randomization in a 1:1 ratio to receive ticagrelor or prasugrel for 5 weeks followed by a direct cross over to the alternative treatment for 5 additional weeks. Brachial artery flow-mediated dilation, inflammatory markers, and number of circulating EPCs were compared.Improvement in brachial artery flow-mediated dilation was greater in the ticagrelor group (0.15 ± 0.19 mm vs. -0.03 ± 0.18 mm; p < 0.001). Moreover, ticagrelor compared with prasugrel decreased interleukin 6 (-0.58 ± 0.43 pg/ml vs. -0.05 ± 0.24 pg/ml; p < 0.001), tumor necrosis factor alpha (-5.62 ± 4.40 pg/ml vs. -0.42 ± 2.64 pg/ml; p < 0.001), and increased adiponectin (2.31 ± 2.00 μg/ml vs. 0.08 ± 1.50 μg/ml; p < 0.001) during 10-week follow-up. Other inflammatory cytokines like high-sensitivity C-reactive protein and soluble vascular cell adhesion molecule-1 were decreased in both groups. Ticagrelor compared with prasugrel significantly increased absolute numbers of circulating EPCs CD34+/KDR+ (42.5 ± 37.8 per μl vs. -28.2 ± 23.7 per μl; p < 0.001), CD34+/CD117+ (51.9 ± 77.2 per μl vs. -66.3 ± 45.2 per μl; p < 0.001), and CD34+/CD133+ (55.2 ± 69.2 per μl vs. -28.0 ± 34.1 per μl; p < 0.001).Compared with prasugrel, ticagrelor significantly decreased inflammatory cytokines such as interleukin 6 and tumor necrosis factor alpha and increased circulating EPCs, contributing to improved arterial endothelial function in diabetic non-ST-segment elevation acute coronary syndrome patients. Thus, data support that pleiotropic effects of ticagrelor beyond its potent antiplatelet effects could contribute to additional clinical benefits. (Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome [NSTE-ACS] Requiring Coronary Stenting; NCT02487732)." @default.
• W2747484920 created "2017-08-31" @default.
• W2747484920 creator A5025828391 @default.
• W2747484920 creator A5026684456 @default.
• W2747484920 creator A5034687612 @default.
• W2747484920 creator A5037058160 @default.
• W2747484920 creator A5037704369 @default.
• W2747484920 creator A5040609689 @default.
• W2747484920 creator A5046555008 @default.
• W2747484920 creator A5049517139 @default.
• W2747484920 creator A5067351808 @default.
• W2747484920 creator A5081739170 @default.
• W2747484920 date "2017-08-01" @default.
• W2747484920 modified "2023-10-02" @default.
• W2747484920 title "Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting" @default.
• W2747484920 cites W136622145 @default.
• W2747484920 cites W1776221901 @default.
• W2747484920 cites W2006052369 @default.
• W2747484920 cites W2019661749 @default.
• W2747484920 cites W2022714839 @default.
• W2747484920 cites W2027045198 @default.
• W2747484920 cites W2027589607 @default.
• W2747484920 cites W2029847191 @default.
• W2747484920 cites W2038602682 @default.
• W2747484920 cites W2064667702 @default.
• W2747484920 cites W2070685693 @default.
• W2747484920 cites W2076048601 @default.
• W2747484920 cites W2085260510 @default.
• W2747484920 cites W2091815611 @default.
• W2747484920 cites W2107033610 @default.
• W2747484920 cites W2115564331 @default.
• W2747484920 cites W2117924455 @default.
• W2747484920 cites W2121390412 @default.
• W2747484920 cites W2127070756 @default.
• W2747484920 cites W2127872440 @default.
• W2747484920 cites W2135104111 @default.
• W2747484920 cites W2153443504 @default.
• W2747484920 cites W2159140695 @default.
• W2747484920 cites W2163901715 @default.
• W2747484920 cites W2169387542 @default.
• W2747484920 cites W2170741125 @default.
• W2747484920 cites W2492363375 @default.
• W2747484920 cites W2510902864 @default.
• W2747484920 cites W2546566703 @default.
• W2747484920 cites W2559492076 @default.
• W2747484920 cites W284112561 @default.
• W2747484920 cites W2885039883 @default.
• W2747484920 cites W3183915260 @default.
• W2747484920 cites W4210547525 @default.
• W2747484920 doi "https://doi.org/10.1016/j.jcin.2017.05.064" @default.
• W2747484920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28838475" @default.
• W2747484920 hasPublicationYear "2017" @default.
• W2747484920 type Work @default.
• W2747484920 sameAs 2747484920 @default.
• W2747484920 citedByCount "75" @default.
• W2747484920 countsByYear W27474849202017 @default.
• W2747484920 countsByYear W27474849202018 @default.
• W2747484920 countsByYear W27474849202019 @default.
• W2747484920 countsByYear W27474849202020 @default.
• W2747484920 countsByYear W27474849202021 @default.
• W2747484920 countsByYear W27474849202022 @default.
• W2747484920 countsByYear W27474849202023 @default.
• W2747484920 crossrefType "journal-article" @default.
• W2747484920 hasAuthorship W2747484920A5025828391 @default.
• W2747484920 hasAuthorship W2747484920A5026684456 @default.
• W2747484920 hasAuthorship W2747484920A5034687612 @default.
• W2747484920 hasAuthorship W2747484920A5037058160 @default.
• W2747484920 hasAuthorship W2747484920A5037704369 @default.
• W2747484920 hasAuthorship W2747484920A5040609689 @default.
• W2747484920 hasAuthorship W2747484920A5046555008 @default.
• W2747484920 hasAuthorship W2747484920A5049517139 @default.
• W2747484920 hasAuthorship W2747484920A5067351808 @default.
• W2747484920 hasAuthorship W2747484920A5081739170 @default.
• W2747484920 hasConcept C126322002 @default.
• W2747484920 hasConcept C164705383 @default.
• W2747484920 hasConcept C201750760 @default.
• W2747484920 hasConcept C2777028646 @default.
• W2747484920 hasConcept C2777698277 @default.
• W2747484920 hasConcept C2780400711 @default.
• W2747484920 hasConcept C2780890252 @default.
• W2747484920 hasConcept C28328180 @default.
• W2747484920 hasConcept C49059817 @default.
• W2747484920 hasConcept C500558357 @default.
• W2747484920 hasConcept C54355233 @default.
• W2747484920 hasConcept C71924100 @default.
• W2747484920 hasConcept C86803240 @default.
• W2747484920 hasConceptScore W2747484920C126322002 @default.
• W2747484920 hasConceptScore W2747484920C164705383 @default.
• W2747484920 hasConceptScore W2747484920C201750760 @default.
• W2747484920 hasConceptScore W2747484920C2777028646 @default.
• W2747484920 hasConceptScore W2747484920C2777698277 @default.
• W2747484920 hasConceptScore W2747484920C2780400711 @default.
• W2747484920 hasConceptScore W2747484920C2780890252 @default.
• W2747484920 hasConceptScore W2747484920C28328180 @default.
• W2747484920 hasConceptScore W2747484920C49059817 @default.
• W2747484920 hasConceptScore W2747484920C500558357 @default.
• W2747484920 hasConceptScore W2747484920C54355233 @default.
• W2747484920 hasConceptScore W2747484920C71924100 @default.

• next